Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

This study has been terminated.
(Interim analysis determined the study did not meet criteria to proceed)
Sponsor:
Information provided by (Responsible Party):
Jordan Berlin, MD, Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier:
NCT01365910
First received: June 1, 2011
Last updated: August 24, 2014
Last verified: August 2014
  Purpose

This phase II trial studies how well Linifanib works in treating patients with advanced, refractory colorectal cancer expressing k-Ras mutations. Linifanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Condition Intervention Phase
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer
Drug: linifanib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Investigator Initiated, Phase II Study of Linifanib in Patients With Advanced, Refractory Colorectal Cancer Expressing Mutated kRas

Resource links provided by NLM:


Further study details as provided by Vanderbilt-Ingram Cancer Center:

Primary Outcome Measures:
  • Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15% [ Time Frame: Baseline and every 8 weeks, up to 2 years ] [ Designated as safety issue: No ]
    Per Response Evaluation in Solid Tumors (RECIST) criteria v. 1.1: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) > 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions. Defined as the CR + PR recorded from the start of the treatment until disease progression/recurrence, the exact two-sided 95% confidence intervals will be reported.


Secondary Outcome Measures:
  • Progression-free Survival [ Time Frame: Every 3 months, up to 2 years ] [ Designated as safety issue: No ]
    Estimated probable duration of life without disease progression, from on‐study date to earlier of progression date or date of death from any cause, using the Kaplan‐Meier method with censoring. Disease progression is defined under RECIST v1.1 as >=20% increase in sum of longest diameters of target lesions, unequivocal progression of non‐target lesions, or appearance of new lesions.

  • Overall Survival [ Time Frame: Every 3 months, up to 2 years ] [ Designated as safety issue: No ]
    Estimated probable duration of life from on‐study date to date of death from any cause, using the Kaplan‐Meier method with censoring.

  • Number of Patients With Each Worst‐Grade Toxicity [ Time Frame: date on‐study up to 2 years following final dose of study ] [ Designated as safety issue: Yes ]

    Count of patients according to the worst‐grade toxicity experienced by each, where worst‐grade toxicity is per NCI common toxicity criteria: grade 1= mild; grade 2 = moderate; grade 3 = severe; grade 4 = life‐threatening; grade 5 = death

    Assessed: days 1 &15 of cycle 1; day 1 of each subsequent 28-day cycle; at 30-day follow-up for two years



Enrollment: 30
Study Start Date: June 2011
Study Completion Date: June 2013
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (enzyme inhibitor)
Patients receive linifanib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: linifanib
Given PO
Other Names:
  • ABT-869
  • multitargeted receptor tyrosine kinase inhibitor ABT-869

Detailed Description:

PRIMARY OBJECTIVES:

I. To achieve an overall response rate of 15% or more.

SECONDARY OBJECTIVES:

I. Determine progression free survival. II. Determine overall survival. III. Evaluate toxicity profile of ABT 869 (linifanib) in this patient population.

OUTLINE:

Patients receive Linifanib orally (PO) once daily (QD). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, every 3 months for 2 years, and then every 6 months for 3 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed colorectal cancer refractory to at least 1 but no more than 3 systemic chemotherapy regimens
  • Patients must have received one standard chemotherapy regimen in the metastatic setting
  • Established Ras-mutant tumor status (archived specimens are okay and this test can have been performed at local laboratories)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • The subject must have adequate bone marrow and organ function, defined as follows:
  • Hemoglobin ≥ 9g/dL
  • Platelets >100,000,
  • Absolute neutrophil count (ANC) > 1000/uL,
  • Serum creatinine < 1.5 x upper limit of normal,
  • Total bilirubin < 1.5 x the upper limit of normal,
  • AST and ALT ≤ 2.0 x upper limit of normal (or ≤ 5 x ULN in the presence of liver metastases)
  • Measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan or magnetic resonance imaging (MRI) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 7 days of study treatment; surgically sterile and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-child-bearing potential
  • Female subjects of child-bearing potential and male subjects must agree to use adequate contraception prior to study entry, for the duration of study participation and up to two months after the last dose of ABT 869; adequate contraception methods should be used consistently and correctly and include the following:
  • Total abstinence from sexual intercourse (minimum one complete menstrual cycle)
  • A vasectomized partner
  • Hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration
  • Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream)
  • The subject must be willing and able to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations
  • The subject must have given written informed consent prior to the initiation of any screening or study-specific procedures
  • Ability to understand and the willingness to sign a written informed consent; a signed informed consent must be obtained prior to any study-specific procedures
  • Patients must be at least 14 days status post last day of prior chemotherapy (at least 28 days since last dose of bevacizumab) and have recovered to grade =< 1 from all chemotherapy-associated side effects
  • Patients must have the ability to swallow pills

Exclusion Criteria:

  • Untreated central nervous system (CNS) metastases; patients may have CNS metastases from any timeframe as long as they are treated and not progressing; brain imaging is not required if there is no clinical suspicion of brain metastases
  • Pregnant or lactating females are excluded
  • Uncontrolled hypertension defined as systolic blood pressure (BP) > 140 and/or diastolic BP > 90 initially evaluated on day of study eligibility determination (when laboratory parameters are assessed), but must be maintained on day of study initiation; (If a patient is found to have a value outside the range above, repeat BP may be assessed and if at subsequent readings x 2 (taken in clinic at least 15 minutes apart) criteria are met, the patient can then be eligible; initiation or modification of antihypertensives is allowed to achieve adequate BP for eligibility; finally, in the case that subsequent determinations are required, the BP assessment that counts towards eligibility is the reading on the day of study initiation); (note: a clinic BP reading without the patient having been at rest for 15 minutes or with the wrong cuff size can be repeated the same day for eligibility criteria to be determined
  • Active bleeding or history of bleeding from cancer related events
  • History of cerebral vascular accident (CVA) or transient ischemic attack (TIA) or recent myocardial infarction (MI) (< 6 months)
  • Active ulcerative colitis, Crohn's disease or Celiac disease that could interfere with the absorption of the drug
  • Current use of therapeutic anticoagulation; low dose anticoagulation for catheter prophylaxis is permitted; Lovenox is permitted for prophylaxis; (Note: patients who develop thrombosis and are placed on anticoagulation while on this trial may continue on study at the discretion of the investigator)
  • The subject has had major surgery within 28 days of Study Day 1
  • The subject has had radiation therapy within 14 days of Study Day 1
  • The subject had prior bevacizumab within 28 days of study day 1
  • No prior treatment with vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors; prior treatment with other investigational agents is allowed
  • The subject has a medical condition, which in the opinion of the study investigator, places them at unacceptably high risk for toxicities
  • Other active malignancy for which the patient has been treated within the past one year
  • Subjects with known human immunodeficiency virus (HIV) infection are excluded
  • Subject has documented left ventricular ejection fraction (LVEF) < 50%
  • Subject has Proteinuria > grade 1 at baseline measured by urine dipstick (2+ or greater) and confirmed by 24 hour (hr) urine collection (> = 1g/24hrs)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01365910

Locations
United States, Tennessee
Vanderbilt Cool Springs
Franklin, Tennessee, United States, 37067
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232-6838
Sponsors and Collaborators
Vanderbilt-Ingram Cancer Center
Investigators
Principal Investigator: Jordan Berlin, MD Vanderbilt-Ingram Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Jordan Berlin, MD, Professor of Medicine; Clinical Director, GI Oncology Program; Director, Phase I Program; Medical Director, Clinical Trials Shared Resources; Medical Oncologist, Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier: NCT01365910     History of Changes
Other Study ID Numbers: VICC GI 1058, NCI-2011-00833
Study First Received: June 1, 2011
Results First Received: June 13, 2014
Last Updated: August 24, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Colonic Neoplasms
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases

ClinicalTrials.gov processed this record on August 26, 2014